NeoGenomics Q2 Revenues Rise 33 Percent on Test Volume | GenomeWeb

NEW YORK (GenomeWeb) – Cancer genetics diagnostics firm NeoGenomics today said that revenues in the second quarter increased 33 percent year over year while test volume increased 40 percent.

During the three months ended June 30, the Ft. Myers, Fla.-based company recorded $20.7 million in revenues, up from $15.6 million in the year-ago quarter. It beat the consensus analyst estimate of $19.8 million.

The number of tests performed in the quarter was up to 45,475 from 32,519 a year ago.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: new chromatin imaging approach, and more.

University of Wisconsin researchers uncover a mutation linked to Mauriac syndrome, which affects some children with type 1 diabetes.

Theranos has hired executives to oversee compliance and regulatory issues, the Wall Street Journal reports.

Chinese researchers to embark on a trial using a CRISPR/Cas9-based immunotherapy next month, Nature News reports.